reports
Otonomy Announces Change in Stock Exchange Listing
Otonomy Announces Change in Stock Exchange Listing SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company’s shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications ...
Otonomy Provides Corporate Update
Otonomy Provides Corporate Update SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of...
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corp...
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update Evaluation of strategic options to realize value from pipeline is ongoing SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no c...
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Dos...
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex dose-response relationship that has been observed with neurotrophinsOtonomy intends to explore strategic options to advance and realize value from its pipeline including both OTO-413 and OTO-825 SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical c...
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Pati...
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other measures to extend its cash runway Clinical focus shifts to OTO-413 following positive Phase 2a results in April 2022; top-line results for evaluation of higher dosing still expected in fourth quarter of 2022 SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical com...
Otonomy Reports Second Quarter 2022 Financial Results and Provides Cor...
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment completed for higher dose evaluation with top-line results expected in fourth quarter of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital...
Otonomy to Report Second Quarter 2022 Financial Results and Provide Co...
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at and will be archived there for 30 days. To access the live call by phone, pleas...
Otonomy to Participate in the H.C. Wainwright Global Investment Confer...
Otonomy to Participate in the H.C. Wainwright Global Investment Conference SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Conference (Hybrid Conference). A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on May 24, 2022. A link to the presentation will also become available at the same time thr...
Otonomy Announces OTO-825 Presentation at the American Society of Gene...
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene & Cell Therapy (ASGCT) Meeting being held May 16-19 in Washington, DC. Dr. Phillip Uribe from Otonomy will be making a podium presentation entitled “Preclinical Development of an AAV-based Gene Therapy (OTO-825) ...
Otonomy Reports First Quarter 2022 Financial Results and Provides Corp...
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoingOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SA...
Otonomy to Report First Quarter 2022 Financial Results and Provide Cor...
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2022 and provide a corporate update at 4:30 p.m. ET on May 9, 2022. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 5359095. A live webcast of the call will b...
Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial...
Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability findings from previous Phase 1/2 trialEnrollment in higher dose cohorts is ongoing with results expected in second half of 2022Otonomy expects to initiate full dose-ranging Phase 2 efficacy trial by the end of 2022 Management will review results during a conference call today at 8:30 a.m. ET...
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
Otonomy to Host Virtual Investor R&D Event on March 22, 2022 SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it will host a virtual Investor R&D Event from 10 a.m. - Noon ET on March 22, 2022. This event will include presentations by key opinion leaders who will provide background information on tinnitus and hearing loss, and review the positive Phase 1/2 trial results for Otonomy’s OTO-313 and OTO-413 product candidates that target these c...
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results an...
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in hearing loss fully enrolled with top-line results expected early in second quarter of 2022; enrollment ongoing for higher dose evaluationOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into secon...
Otonomy to Participate in Two Upcoming Investor Conferences
Otonomy to Participate in Two Upcoming Investor Conferences SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in the following virtual investor conference events: Cowen 42nd Annual Health Care Conference: The “Auditory and Ophthalmology” panel session on March 7, 2022 at 2:10 p.m. ET / 11:10 a.m. PT;Cowen 42nd Annual Health Care Conference: A fireside chat on March 8, 2022 at 1:30 p.m. ET / 10:30 a.m. PT; andOppenhe...
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
Otonomy to Host Virtual Investor R&D Event on March 22, 2022 SAN DIEGO, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it will host a virtual Investor R&D Event from 10 a.m. - Noon ET on March 22, 2022. This event will include presentations by key opinion leaders who will provide background information on tinnitus and hearing loss and review the positive Phase 1/2 trial results for Otonomy’s OTO-313 and OTO-413 product candidates that target these c...
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in T...
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus OTO-313 Phase 2 trial is fully enrolled ahead of scheduleTop-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the completion of patient enrollment in the Phase 2 clinical trial of OTO-313 in tinnitus. The randomized, double-blind, placebo-controlled trial enrolled 153 patients with persistent, unilateral tinnitus of a...
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results ...
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2021 and provide a corporate update at 4:30 p.m. ET on February 28, 2022. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 51693...
Otonomy Announces OTO-413 Presentations at American Auditory Society A...
Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two upcoming presentations on the OTO-413 hearing loss program at the 49th Annual Scientific and Technology Meeting of the American Auditory Society (AAS) to be held February 24-26, 2022 in Scottsdale, Arizona. These include a podium presentation of previously disclosed results from the OTO-413 Phase 1/2 clinical tri...
Otonomy Announces Multiple Presentations at Association for Research i...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting, to be held virtually during February. Otonomy is participating in a workshop entitled “Translational delivery approaches for inner ear therapies” that will be held from 11 a.m. to 1...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.